We are live on ! Find out more
XBIT icon

XBiotech
XBIT

38 hedge funds and large institutions have $28.1M invested in XBiotech in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

394% more capital invested

Capital invested by funds: $5.68M → $28.1M (+$22.4M)

325% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 4

52% more funds holding

Funds holding: 25 → 38 (+13)

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

3.94% more ownership

Funds ownership: 3.12% → 7.06% (+3.9%)

72% less call options, than puts

Call options by funds: $387K | Put options by funds: $1.38M

Holders
38
Holders Change
+13
Holders Change %
+52%
% of All Funds
0.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
9
Reduced
7
Closed
4
Calls
$387K
Puts
$1.38M
Net Calls
-$988K
Net Calls Change
-$728K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.31M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$2.2M
3
SI
Sofinnova Investments
California
+$2.12M
4
Millennium Management
Millennium Management
New York
+$1.32M
5
Barclays
Barclays
United Kingdom
+$645K

Top Sellers

Rank Fund Capital Flow
1
EI
EAM Investors
California
-$286K
2
Group One Trading
Group One Trading
Illinois
-$114K
3
BFM
Boothbay Fund Management
New York
-$107K
4
VF
Virtu Financial
New York
-$80K
5
UBS Group
UBS Group
Switzerland
-$53K
Name Holding Trade Value Shares
Change 		Change in
Stake
Verition Fund Management
26
Verition Fund Management
Connecticut
$135K +$99.6K +12,290 New
BC
27
Birchview Capital
Vermont
$110K +$81.1K +10,000 New
Morgan Stanley
28
Morgan Stanley
New York
$97K +$71.6K +8,826 New
Group One Trading
29
Group One Trading
Illinois
$47K -$114K -14,029 -77%
CLOS
30
Compagnie Lombard Odier SCmA
Switzerland
$44K +$32.4K +4,000 New
Royal Bank of Canada
31
Royal Bank of Canada
Ontario, Canada
$39K +$10.5K +1,299 +58%
TRCT
32
Tower Research Capital (TRC)
New York
$29K +$21K +2,586 New
Simplex Trading
33
Simplex Trading
Illinois
$12K +$9.46K +1,167 New
Wells Fargo
34
Wells Fargo
California
$11K -$32.4K -4,000 -80%
Bank of Montreal
35
Bank of Montreal
Ontario, Canada
$2K – – –
MWNA
36
Marshall Wace North America
New York
$2K +$1.74K +215 New
BNP Paribas Financial Markets
37
BNP Paribas Financial Markets
France
$606 – – –
BFM
38
Boothbay Fund Management
New York
– -$107K -21,079 Closed
VF
39
Virtu Financial
New York
– -$80K -15,682 Closed
UBS Group
40
UBS Group
Switzerland
– -$53K -10,493 Closed
CS
41
Credit Suisse
Switzerland
– -$51K -10,026 Closed
1
2

XBIT Hedge Fund Activity: Q1 2019 in Review

38 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q1 2019, worth a combined $28.1M — up 394% from $5.68M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new XBIT positions and 4 closed out — a net gain of 13 holders — while 9 added to existing stakes and 7 trimmed.

The largest buyer was Vanguard Group, adding an estimated $2.31M. The largest seller was EAM Investors, cutting an estimated $286K.

  • 38 institutional investors held XBiotech (XBIT) as of Q1 2019, up from 25 in Q4 2018.
  • Funds reported $28.1M of XBiotech stock for Q1 2019, up 394% quarter-over-quarter.
  • 17 funds opened new XBiotech positions in Q1 2019 and 4 closed out, a net change of +13 holders.
  • The largest XBiotech buyer in Q1 2019 was Vanguard Group, an estimated $2.31M added.
  • The largest XBiotech seller in Q1 2019 was EAM Investors, an estimated $286K sold.

Based on aggregated 13F filings for Q1 2019.